Biotech Venture Capitalists Face New Challenges as Traditional Drug Development Strategies Are Upended

For many years, venture capitalists in biotech have depended on a well-established formula to generate profits through drug development. However, this reliable method is now being challenged by rapid changes in the industry, forcing investors to adapt to new trends and uncertainties.